Institut für Pharmazeutische und Medizinische Chemie, Westfälische Wilhelms-Universität, 48149 Münster, Germany.
Brain Res. 2012 Apr 11;1448:20-6. doi: 10.1016/j.brainres.2012.02.016. Epub 2012 Feb 13.
In previous work, we have demonstrated by radiolabeling, mass spectrometry and site-directed mutagenesis that nerve growth factor (NGF) as well as brain-derived neurotrophic factor (BDNF) and fibroblast growth factor 2 (FGF2) are capable of ATP-binding and that this binding appears to be essential for their neuroprotective activity. In this study, we attempted to shed some light on the question whether ATP is a general prerequisite for neuroprotection. Therefore, we used the non-ATP-binding granulocyte colony-stimulating factor (GCSF), the calcium antagonist nimodipine and the NMDA antagonist dizocilpine to find out whether they need ATP for neuroprotection comparable to NGF and BDNF. However, ATP was not necessary for the neuroprotective effects of GCSF, nimodipine and dizocilpine on primary cultures of rat cortical neurons damaged by oxygen-glucose deprivation whereas neuroprotection was demonstrable for NGF and BDNF only when ATP was present in the culture medium at a concentration higher than ca. 0.4nmol/l. In circular dichroism studies ATP caused changes of the secondary structure of NGF but not of GCSF. Taken together, we suggest that ATP is not a general prerequisite for neuroprotectivity but some growth factors like NGF and BDNF can stimulate their receptors only if they have bound ATP.
在以前的工作中,我们通过放射性标记、质谱分析和定点突变证明,神经生长因子(NGF)以及脑源性神经营养因子(BDNF)和纤维母细胞生长因子 2(FGF2)能够结合 ATP,并且这种结合似乎对它们的神经保护活性是必需的。在这项研究中,我们试图阐明一个问题,即 ATP 是否是神经保护的一般前提条件。因此,我们使用非 ATP 结合的粒细胞集落刺激因子(GCSF)、钙拮抗剂尼莫地平(nimodipine)和 NMDA 拮抗剂地卓西平(dizocilpine),以了解它们是否需要与 NGF 和 BDNF 相当的 ATP 来实现神经保护。然而,对于氧葡萄糖剥夺损伤的大鼠皮质神经元原代培养物,GCSF、尼莫地平(nimodipine)和地卓西平(dizocilpine)的神经保护作用并不需要 ATP,而 NGF 和 BDNF 的神经保护作用只有在培养基中存在高于约 0.4nmol/L 的 ATP 时才能证明。圆二色性研究表明,ATP 引起了 NGF 的二级结构变化,但没有引起 GCSF 的变化。综上所述,我们认为 ATP 不是神经保护的一般前提条件,但有些生长因子,如 NGF 和 BDNF,只有在结合了 ATP 后才能刺激它们的受体。